(Q38612623)

4 September 2017

Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors (English)

1 reference

4 September 2017

0 references

1 reference

A Santoro

1

1 reference

4 September 2017

A Romanini

2

1 reference

4 September 2017

A Rosso

3

1 reference

4 September 2017

S Frustaci

4

1 reference

4 September 2017

A Comandone

5

1 reference

4 September 2017

G Apice

6

1 reference

4 September 2017

D De Toma

7

1 reference

4 September 2017

L Dogliotti

8

1 reference

4 September 2017

R Lionetto

9

1 reference

4 September 2017

C Dani

10

1 reference

4 September 2017

P Bruzzi

11

1 reference

4 September 2017

M Piolini

12

1 reference

4 September 2017

P Bergnolo

13

1 reference

4 September 2017

C Verusio

14

1 reference

4 September 2017

language of work or name

1 reference

1 January 1999

1 reference

4 September 2017

1 reference

4 September 2017

3

1 reference

4 September 2017

3-4

1 reference

4 September 2017

177-181

1 reference

Creative Commons Attribution 3.0 Unported

4 September 2017

start time

1 January 1999

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395431

Phase II study of docetaxel in advanced soft tissue sarcomas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395431

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395431

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395431

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395431

Optimal two-stage designs for phase II clinical trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395431

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

23 June 2018

1 reference

12 December 2020

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

12 December 2020

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

12 December 2020

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

12 December 2020

Identifiers

DOI

10.1080/13577149977613

1 reference

4 September 2017

1 reference

4 September 2017

PubMed publication ID

18521282

1 reference